Black Diamond Therapeutics, Inc. (BDTX) vs The Joint Corp. (JYNT)
A side-by-side comparison of Black Diamond Therapeutics, Inc. and The Joint Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BDTX
Black Diamond Therapeutics, Inc.
$1.86HealthcareDelayed quote: Oct 6, 2026, 10:45 AM EDT
JYNT
The Joint Corp.
$7.10HealthcareDelayed quote: Oct 6, 2026, 10:39 AM EDT
Total return — BDTX vs JYNT
growth of $100 · dividends reinvested · last 7yBDTX -95.1% (-35.0%/yr)JYNT -58.3% (-11.8%/yr)JYNT compounded faster over this window
Log scale — wide-divergence pair
BDTX JYNT
BDTX vs JYNT: by the numbers
- •BDTX is the larger company ($107M vs $101M market cap).
- •BDTX converts more revenue to profit (31.95% vs 6.49% net margin).
Metrics side by side
Valuation
| Metric | BDTX | JYNT |
|---|---|---|
| P/E ratio | N/A | 26.78 |
| Forward P/E | N/A | 29.58 |
| P/S ratio | N/A | 1.73 |
| P/B ratio | 1.11 | 6.39 |
| EV / EBITDA | N/A | 25.66 |
| FCF yield | N/A | 4.18% |
Profitability
| Metric | BDTX | JYNT |
|---|---|---|
| Gross margin | 99.54% | 81.08% |
| Operating margin | 28.39% | 2.45% |
| Net margin | 31.95% | 6.49% |
| ROE | -44.29% | 23.96% |
| ROIC | -47.54% | 5.11% |
Growth (annualized)
| Metric | BDTX | JYNT |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -3.57% |
| EPS CAGR (5Y) | N/A | -27.37% |
| FCF CAGR (5Y) | N/A | -16.35% |
| Total return CAGR (5Y) | -24.47% | -40.34% |
Frequently asked
- Is BDTX or JYNT more profitable?
- BDTX runs the higher net margin — BDTX at 31.95% versus JYNT at 6.49%.
- How have BDTX and JYNT total returns compared?
- Over the past 5 years, BDTX delivered -24.47% and JYNT delivered -40.34% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Joint P/E ratioBlack Diamond Therapeutics ROEJoint ROEBlack Diamond Therapeutics operating marginJoint operating marginBlack Diamond Therapeutics revenue growthJoint revenue growthBlack Diamond Therapeutics free cash flowJoint free cash flow
Black Diamond Therapeutics & Joint appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.